<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36645">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01674621</url>
  </required_header>
  <id_info>
    <org_study_id>BA058-05-007</org_study_id>
    <secondary_id>2012-001921-29</secondary_id>
    <nct_id>NCT01674621</nct_id>
  </id_info>
  <brief_title>Phase 2 Study of BA058 (Abaloparatide) Transdermal Delivery in Postmenopausal Women With Osteoporosis</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 (Abaloparatide) Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal (Abaloparatide Transdermal)) in Healthy Postmenopausal Women With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radius Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nordic Bioscience A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Radius Health, Inc.</source>
  <oversight_info>
    <authority>Hong Kong: Department of Health</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Denmark: Danish Medicines Agency</authority>
    <authority>Estonia: The State Agency of Medicine</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the clinical safety and efficacy of BA058 Transdermal in otherwise healthy
      postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD)
      and serum markers of bone metabolism when compared to Transdermal Placebo and BA058
      Injection for 6 months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>BMD (Lumbar Spine)</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in BMD, using DXA results; active compared to placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BMD (Hip and Forearm)</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in BMD, using DXA results; active compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum markers of bone formation and resorption</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in laboratory results; active compared to placebo.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Physical examinations, vital signs, electrocardiograms, clinical laboratory tests, local tolerance, and adverse events.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Post Menopausal Osteoporosis</condition>
  <arm_group>
    <arm_group_label>BA058 (Abaloparatide) Transdermal Placebo (0 mcg)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>BA058 (Abaloparatide) Transdermal Microneedle Patch 0 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 (Abaloparatide) Transdermal (50 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BA058 (Abaloparatide)Transdermal Microneedle Patch - 50 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 (Abaloparatide) Transdermal (100 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BA058 (Abaloparatide) Transdermal Microneedle Patch - 100 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 (Abaloparatide) Transdermal (150 mcg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BA058 (Abaloparatide) Transdermal Microneedle Patch - 150 mcg daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BA058 (Abaloparatide) Injection (80 mcg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BA058 (Abaloparatide-SC) Subcutaneous Injection - 80 mcg daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Placebo</intervention_name>
    <description>BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months</description>
    <arm_group_label>BA058 (Abaloparatide) Transdermal Placebo (0 mcg)</arm_group_label>
    <other_name>Abaloparatide Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Transdermal (50 mcg)</intervention_name>
    <description>BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months</description>
    <arm_group_label>BA058 (Abaloparatide) Transdermal (50 mcg)</arm_group_label>
    <other_name>Abaloparatide Transdermal (50 mcg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Transdermal (100 mcg)</intervention_name>
    <description>BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months</description>
    <arm_group_label>BA058 (Abaloparatide) Transdermal (100 mcg)</arm_group_label>
    <other_name>Abaloparatide Transdermal (100 mcg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Transdermal (150 mcg)</intervention_name>
    <description>BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months</description>
    <arm_group_label>BA058 (Abaloparatide) Transdermal (150 mcg)</arm_group_label>
    <other_name>Abaloparatide Transdermal (150 mcg)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BA058 Injection (80 mcg)</intervention_name>
    <description>BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months</description>
    <arm_group_label>BA058 (Abaloparatide) Injection (80 mcg)</arm_group_label>
    <other_name>Abaloparatide Injection (80 mcg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Postmenopausal woman, less than 85 years old.

          -  BMD T-score ≤ -2.5 of spine or hip (femoral neck) or ≤ -2.0 with previous fracture
             (within 5 years).

          -  Normal physical exam, vital signs, electrocardiogram (ECG) and medical history.

          -  Laboratory tests within the normal range including serum calcium, Vit D, PTH(1-84),
             serum phosphorus and alkaline phosphatase.

        Exclusion Criteria:

          -  BMD T-score ≤ -5.0 at the lumbar spine or hip.

          -  History of bone disorders (e.g., Paget's disease) other than postmenopausal
             osteoporosis.

          -  Significantly impaired renal function.

          -  History of any cancer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ballerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vejie</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Hong Kong</country>
    <country>Poland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 26, 2014</lastchanged_date>
  <firstreceived_date>August 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BA058</keyword>
  <keyword>Abaloparatide</keyword>
  <keyword>Osteo</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Transdermal</keyword>
  <keyword>Patch</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
